1. Shigeyasu, Kunitoshi, Okugawa, Yoshinaga, Toden, Shusuke, Chen, Leilei, Goel, Ajay. 2018. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. In JCI insight, 3, . doi:10.1172/jci.insight.99976. https://pubmed.ncbi.nlm.nih.gov/29925690/
2. Wei, Yan, Zhang, Haowan, Feng, Qiaohui, Peng, Xinxin, Xu, Xiaoyan. 2022. A novel mechanism for A-to-I RNA-edited AZIN1 in promoting tumor angiogenesis in colorectal cancer. In Cell death & disease, 13, 294. doi:10.1038/s41419-022-04734-8. https://pubmed.ncbi.nlm.nih.gov/35365616/
3. Paris, Andrew J, Snapir, Zohar, Christopherson, Cindy D, Kahana, Chaim, Friedman, Scott L. . A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. In Hepatology (Baltimore, Md.), 54, 2198-207. doi:10.1002/hep.24608. https://pubmed.ncbi.nlm.nih.gov/21837750/
4. Nakamura, Keiichiro, Shigeyasu, Kunitoshi, Okamoto, Kazuhiro, Matsuoka, Hirofumi, Masuyama, Hisashi. 2022. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. In Gynecologic oncology, 166, 326-333. doi:10.1016/j.ygyno.2022.05.026. https://pubmed.ncbi.nlm.nih.gov/35697535/
5. Zeng, Xinyi, Du, Shen, Geng, Lou, Ma, Jiexian. . Nc-RNA-mediated low expression of AZIN1 correlated with unfavorable prognosis in kidney renal clear cell carcinoma. In Cancer medicine, 13, e70105. doi:10.1002/cam4.70105. https://pubmed.ncbi.nlm.nih.gov/39140420/
6. Juszczak, Grzegorz R, Stankiewicz, Adrian M. 2017. Glucocorticoids, genes and brain function. In Progress in neuro-psychopharmacology & biological psychiatry, 82, 136-168. doi:10.1016/j.pnpbp.2017.11.020. https://pubmed.ncbi.nlm.nih.gov/29180230/
7. Sun, Qiang, Gong, Jinlong, Gong, Xueyi, Zhang, Qiao, Zhu, Xiaofeng. . Long non-coding RNA MALAT1 aggravated liver ischemia-reperfusion injury via targeting miR-150-5p/AZIN1. In Bioengineered, 13, 13422-13436. doi:10.1080/21655979.2022.2073124. https://pubmed.ncbi.nlm.nih.gov/36700468/
智鼠故事 
